JP2022536347A5 - - Google Patents
Info
- Publication number
- JP2022536347A5 JP2022536347A5 JP2021573426A JP2021573426A JP2022536347A5 JP 2022536347 A5 JP2022536347 A5 JP 2022536347A5 JP 2021573426 A JP2021573426 A JP 2021573426A JP 2021573426 A JP2021573426 A JP 2021573426A JP 2022536347 A5 JP2022536347 A5 JP 2022536347A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- amino acid
- substitutions
- antibody
- isolated fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861484P | 2019-06-14 | 2019-06-14 | |
| US62/861,484 | 2019-06-14 | ||
| PCT/US2020/037648 WO2020252421A2 (en) | 2019-06-14 | 2020-06-13 | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536347A JP2022536347A (ja) | 2022-08-15 |
| JP2022536347A5 true JP2022536347A5 (https=) | 2023-08-07 |
| JP7850417B2 JP7850417B2 (ja) | 2026-04-23 |
Family
ID=73782254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573426A Active JP7850417B2 (ja) | 2019-06-14 | 2020-06-13 | 新規インターロイキン－２バリアントおよびその二官能性融合分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220170028A1 (https=) |
| EP (1) | EP3983001A4 (https=) |
| JP (1) | JP7850417B2 (https=) |
| KR (1) | KR20220035122A (https=) |
| CN (1) | CN114728040A (https=) |
| AU (1) | AU2020292421B2 (https=) |
| CA (1) | CA3143038A1 (https=) |
| WO (1) | WO2020252421A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7749319B2 (ja) | 2017-10-10 | 2025-10-06 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用 |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| IL293471A (en) * | 2019-12-17 | 2022-08-01 | Amgen Inc | Dual interleukin-2 / tnf receptor agonist for use in medicine |
| US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
| EP4146684A2 (en) | 2020-05-08 | 2023-03-15 | Alpine Immune Sciences, Inc. | April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4323392A4 (en) * | 2021-04-16 | 2025-03-19 | Orionis Biosciences, Inc. | IL-2-BASED CONSTRUCTS |
| AU2022306974A1 (en) * | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases |
| EP4406965A4 (en) * | 2021-09-22 | 2025-12-17 | Fortvita Biologics Singapore Pte Ltd | INTERLEUKIN-2 MUTANT AND FUSION PROTEIN OF WHICH |
| CN118414160A (zh) * | 2021-10-06 | 2024-07-30 | 艾尔图制药公司 | 对发炎组织具有靶向特异性的白介素2嵌合构建体 |
| WO2023154785A2 (en) * | 2022-02-10 | 2023-08-17 | Orionis Biosciences, Inc. | Il-2 trap molecules |
| EP4499846A1 (en) | 2022-03-25 | 2025-02-05 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
| US20240076343A1 (en) | 2022-06-16 | 2024-03-07 | Cephalon Llc | Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof |
| KR20250057823A (ko) * | 2022-08-29 | 2025-04-29 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Taci 폴리펩티드를 포함하는 융합 단백질 및 이의 용도 |
| WO2024199458A1 (en) * | 2023-03-29 | 2024-10-03 | Wuxi Biologics (Shanghai) Co., Ltd. | Il-2 variants with improved stability and compositions thereof |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| CN121889417A (zh) * | 2023-08-23 | 2026-04-17 | 深水炸弹有限公司 | 促进共价化学缀合的白介素-2变体蛋白及其用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| DK1454138T3 (da) * | 2001-12-04 | 2012-02-13 | Merck Patent Gmbh | Immunocytokiner med moduleret selektivitet |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| US20060234205A1 (en) * | 2004-03-05 | 2006-10-19 | Chiron Corporation | In vitro test system for predicting patient tolerability of therapeutic agents |
| CN102260352B (zh) * | 2010-05-28 | 2013-11-20 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| SG192673A1 (en) * | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| PT3102595T (pt) * | 2014-02-06 | 2019-01-11 | Hoffmann La Roche | Proteínas de fusão de interleucina-2 e suas utilizações |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2769282C2 (ru) * | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN110505883A (zh) * | 2017-04-13 | 2019-11-26 | 豪夫迈·罗氏有限公司 | 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂 |
| US10676516B2 (en) * | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US20200140547A1 (en) * | 2017-05-26 | 2020-05-07 | The Johns Hopkins University | Multifunctional antibody-ligand traps to modulate immune tolerance |
| KR20250156190A (ko) * | 2018-06-22 | 2025-10-31 | 큐진 인크. | 인터루킨-2 변이체 및 이의 사용 방법 |
| EP3980051A4 (en) * | 2019-06-05 | 2023-09-13 | Asher Biotherapeutics, Inc. | FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS |
-
2020
- 2020-06-13 WO PCT/US2020/037648 patent/WO2020252421A2/en not_active Ceased
- 2020-06-13 JP JP2021573426A patent/JP7850417B2/ja active Active
- 2020-06-13 US US17/618,207 patent/US20220170028A1/en active Pending
- 2020-06-13 KR KR1020227001354A patent/KR20220035122A/ko active Pending
- 2020-06-13 EP EP20823570.5A patent/EP3983001A4/en active Pending
- 2020-06-13 CA CA3143038A patent/CA3143038A1/en active Pending
- 2020-06-13 AU AU2020292421A patent/AU2020292421B2/en active Active
- 2020-06-13 CN CN202080057566.1A patent/CN114728040A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022536347A5 (https=) | ||
| JP2022536345A5 (https=) | ||
| JP7317159B2 (ja) | キメラ抗原受容体及びその使用方法 | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| AU2011240624B2 (en) | TRAIL R2-specific multimeric scaffolds | |
| JP2023182757A (ja) | 調整可能な親和性を有する免疫調節タンパク質 | |
| US20210380701A1 (en) | MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES | |
| JP2023506452A5 (https=) | ||
| JP2022504868A (ja) | 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体 | |
| JP2020511949A5 (https=) | ||
| KR20160014010A (ko) | 신규 항체 | |
| JP7356726B2 (ja) | タンパク性ヘテロ二量体及びその使用 | |
| RS55609B1 (sr) | Fc fuzioni proteini koji sadrže nove linkere ili aranžmane | |
| CA2993891A1 (en) | Interleukin-15 fusion proteins for tumor targeting therapy | |
| WO2011076781A1 (en) | Tetravalent cd47-antibody constant region fusion protein for use in therapy | |
| EP3253795A1 (en) | Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JP2018536434A (ja) | 腫瘍形質導入のための組成物及び方法 | |
| CN111423512A (zh) | 阻断血管内皮细胞生长且活化t细胞的多靶向融合蛋白和包含其的药物组合物 | |
| JP7303527B2 (ja) | 新たな結合特異性を抗体に付与する超汎用法 | |
| JP2024535872A5 (https=) | ||
| JP2023527621A5 (https=) | ||
| RU2021139059A (ru) | Новые варианты интерлейкина-2 для лечения рака | |
| WO2026043906A1 (en) | Multi-chain chimeric polypeptides and uses thereof | |
| WO2025160083A1 (en) | Targeted low potency il-12 fc fusion proteins and uses thereof |